
NASDAQHealthcareMedical - Devices
最新数据
US$16.45
+US$0.34 · +2.11%
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
收盘时
US$16.45
+US$0.34 · +2.11%
盘后
US$16.45
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
日内区间
当前US$16.45
52周区间
当前US$16.45
盘中时间采用ET。市场数据可能有所延迟。
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
日内区间
当前US$16.45
52周区间
当前US$16.45
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 10.15亿 USD | 9.4亿 USD | 7.48亿 USD | 8.01亿 USD | 7.03亿 USD |
| 销货成本 | 4.84亿 USD | 4.51亿 USD | 3.8亿 USD | 3.88亿 USD | 3.27亿 USD |
| 毛利 | 5.31亿 USD | 4.9亿 USD | 3.68亿 USD | 4.13亿 USD | 3.76亿 USD |
| 研究与开发 | 1.75亿 USD | 1.99亿 USD | 2.48亿 USD | 1.7亿 USD | 9205.4万 USD |
| 销售、一般及管理费用 | 4.34亿 USD | 3.9亿 USD | 3.53亿 USD | 3.36亿 USD | 2.62亿 USD |
| 营业费用 | 6.09亿 USD | 5.89亿 USD | 6.01亿 USD | 5.06亿 USD | 3.54亿 USD |
| 利息收入 | 908.6万 USD | 1799.3万 USD | 2285.8万 USD | 605.7万 USD | 67.4万 USD |
| 利息支出 | 790.7万 USD | 741.5万 USD | 988.2万 USD | 620.8万 USD | 604万 USD |
| 折旧和摊销 | 1766.6万 USD | 1660.7万 USD | 1571.5万 USD | 1433万 USD | 1384.5万 USD |
| 营业利润 | −7812.2万 USD | −9912.7万 USD | −2.33亿 USD | −9284.8万 USD | 2265.3万 USD |
| 净利润 | −2.05亿 USD | −9602.5万 USD | −2.23亿 USD | −9459.4万 USD | 1556.6万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$26.06
上涨空间 58.42%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2017年10月10日 | 1:10 | — | — |
已生效 2017年10月10日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4813.41万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB3467.47万0.02%1853亿 USD0.03%US$288.16-0.46%
iShares Russell 2000 ETFIWM2930.77万0.04%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap Growth ETFVBK1986.65万0.04%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF1753.3万0.02%954亿 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM1382.84万0.21%64.1亿 USD0.28%US$45.24-0.48%
iShares Russell 2000 Growth ETFIWO1039.75万0.07%139.17亿 USD0.24%US$353.71-0.86%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1021.14万0.06%158.4亿 USD0.03%US$53.42-0.06%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
Fidelity Enhanced Small Cap ETFFESM
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。